Investment Forum Launch Partner
Catalyst Capital Markets
Website: https://www.catalystcapmkts.com/
Catalyst Capital Markets is a specialized capital markets advisory firm dedicated to unlocking growth and opportunity for emerging and established companies. Founded by a team of seasoned senior executives with over 175 years of collective global experience, Catalyst Capital Markets delivers strategic guidance and transaction management across the full spectrum of capital markets activities. The firm’s expertise spans initial public offerings, follow-on transactions, direct listings, up listings, private placements, PIPEs, private credit, mezzanine debt, high-yield bonds, convertible securities, SPAC and De-SPAC advisory, and more.
With a proven track record of advising or executing on more than 1,000 debt and equity transactions over the past four decades, Catalyst Capital Markets leverages deep industry knowledge and a broad investor network to drive differentiated value and outcomes for its clients. The firm’s disciplined, client-focused approach is designed to optimize capital structures, facilitate fundraising, and support strategic corporate actions such as mergers, acquisitions, spin-outs, and divestitures. Headquartered in Bucks County, Pennsylvania, Catalyst Capital Markets is positioned as a trusted partner for companies navigating the complexities of today’s capital markets environment.
Gold Partner
Encoll
Website: https://encoll.com/
EnColl Corporation, established in 1994, is a California corporation that develops, manufactures and markets Type-I collagen-based products. EnColl uses its patented technology for the preparation of high purity and charge modified collagen. The company’s technologies and manufacturing system yields a series of high quality products required for various medical fields such as general and plastic surgery (healing of wounds, burns and dermal ulcers/sores), orthopedic surgery (bone regeneration, spinal fusion), oral surgery (periodontal and dental products), and neurological injuries (brain/nerve regeneration), drug delivery, biopharmaceutical research, and cosmetic & dietary applications.
GR Consulting
Website: https://grconsultingsolutions.com/
GR Consulting (GRc) is a specialized advisory firm focused exclusively on the wound care and surgical wound care markets. We work with start-up and early-stage companies, as well as expanding wound care practices, to provide the strategic support and operational expertise they need to grow effectively. Our team is composed of senior industry professionals with over 200 years of combined experience across key areas including market access, reimbursement, regulatory affairs, health economics and outcomes research (HEOR), clinical trial design and execution, strategic partner development, business operations, and data-driven market research.
GRc’s model is intentionally lean and customizable, offering clients the flexibility and deep expertise of a large firm without the high overhead or one-size-fits-all approach. Whether entering new markets, preparing for a product launch, or navigating reimbursement challenges, GRc delivers targeted solutions aligned with each client’s unique goals. We pride ourselves on being a trusted extension of our clients’ teams—providing leadership, technical ingenuity, and a strong industry network to help turn strategy into successful execution. With a hands-on approach and a focus on meaningful results, GR Consulting is a valuable partner for those driving innovation in wound care.
Knowledge Partner
AOTI
Website: https://aotinc.net/
At AOTI, we are helping all people with chronic conditions get back to living their lives to the fullest. We do this by enhancing access to care, improving clinical outcomes and quality of life, and advancing health equity. AOTI is recognized as a leader in wound care technology around the world and is a founding member of the American Diabetes Association’s - Amputation Prevention Alliance. Our unique multi-modality Topical Wound Oxygen (TWO2) therapy has been proven through Randomized Controlled Trial and Real-World Evidence studies to significantly reduce both Hospitalizations and Amputations over 12 months. Using a combination of non-contact cyclical compression, humidification, and high-pressure delivery of oxygen, AOTI’s TWO2 therapy has shown to provide more effective and durable complete healing in a variety of different wound types, including Diabetic Foot Ulcers, Venous Leg Ulcers and Pressure Ulcers. TWO2 can be administered in any clinical setting or self-administered by the patient at home, overcoming common barriers to access and compliance, thus helping to advance health equity, while improving outcomes and reducing costs.
Bronze Partner
MCRA, an IQVIA business
Website: https://www.mcra.com/
MCRA, an IQVIA business, is a leading therapy focused global full-service medical device, diagnostics & biologics CRO & consulting advisory firm. MCRA is the pioneer and leader in integrating its core service offerings to bring healthcare innovation to the market globally, from conception to commercialization. Our team of industry leading talent, including former FDA reviewers, notified body decision makers, clinical subject matter experts, reimbursement veterans and payers, provides in-depth therapeutic knowledge and thorough market understanding to each project we take..
Exhibitors
Altrazeal
Website: https://altrazeal.com/
Altrazeal Life Sciences Inc. is a specialty medical technology company dedicated to advancing drug delivery systems through its patented innovations. The company’s flagship product, Altrazeal® Transforming Powder Dressing, revolutionizes wound care by forming a conforming, moist dressing upon contact with wound exudate, accelerating healing and optimizing the wound bed environment. This sterile powder dressing is available across all U.S. states and in 17 countries spanning Europe, the Middle East, and Latin America. Altrazeal also pioneers OraDisc, a patented transmucosal drug delivery device designed for localized and systemic treatment via mucosal surfaces. OraDisc is a multi-layered, water-erodible carrier that adheres instantly, minimizes discomfort, and enables tailored therapeutic release over time. With a commitment to innovation and patient-centered solutions, Altrazeal Life Sciences continues to expand its global footprint and redefine standards in wound healing and drug delivery technologies.
Amferia
Website: https://www.amferia.com/
Amferia was founded in 2018 as a spin-off from Chalmers University of Technology, Gothenburg, Sweden. Amferia’s proprietary technology is a new and effective antimicrobial material based on antimicrobial peptides that targets and rapidly kills bacteria upon contact, including numerous antimicrobial resistant bacteria like MRSA and MDR E. Coli.
The material is selective and targets only bacteria while being entirely non-toxic to human and animal cells. Today, the team has transformed this concept into a technology platform, with the first product being an antimicrobial wound care dressing for skin wound applications in human and animal health, supported by strong scientific data. Read more at www.amferia.com
Coldplasmatech
Website: https://coldplasmatech.com/
Coldplasmatech GmbH is a German MedTech innovator transforming wound care with cold atmospheric plasma technology. Based in Greifswald, the company developed the CPT® system – a unique, non-invasive therapy that promotes healing, combats multidrug-resistant bacteria, and stimulates tissue regeneration. The platform consists of the CPTpatch® and CPTcube®, enabling precise, localized treatment for chronic wounds, burns, and surgical sites. Coldplasmatech’s solution is CE-marked (Class IIb) and already in use at leading hospitals and outpatient CPT-Plasma-Competence-Centers in Europe. With strong clinical evidence, international partnerships, and a focus on scalable innovation, Coldplasmatech is redefining wound healing for modern healthcare.
JDL Access
Website: https://jdlaccess.com/
JDL ACCESS
Bridging the Gap to Market Adoption
JDL Access offers comprehensive reimbursement support services designed for medical technology companies. Our mission is to bridge the medical technology gap from commercialization to coverage. We achieve this by creating tailored patient access programs that support individual case coverage, while also providing field market access services to drive broad positive coverage at the payer medical policy level. Through the strategic use of patient appeals and the expertise of our payer advocacy team, we accelerate payer adoption and ensure that groundbreaking medical technologies are accessible to the patients who need them most.
Merakris
Website: https://merakris.com/
Merakris Therapeutics is pioneering biologic drug development by leveraging exosomes, growth factors, and cell-derived proteins from immunologically privileged tissues. The company’s innovative platform harnesses these bioactive components—especially nano vesicles and cytokine-rich formulations—to drive wound healing and tissue regeneration.
Merakris has three commercial products and an active Phase 2b IND-stage drug candidate, MTX-001, a first-in-class, subcutaneous biologic injection for the treatment of venous leg ulcers (VLUs). MTX-001 is a cell-free amniotic wound care liquid that utilizes a potent mix of cytokines and regenerative proteins to initiate and regulate complex biological healing cascades.
PRIA Healthcare
Website: https://priahealthcare.com/who-we-help/medical-device-manufacturers/
PRIA Healthcare is a leading full-spectrum reimbursement services and market access firm, instrumental in the successful commercialization of over 300 medical devices since 2012. As a trusted partner to innovators in MedTech and Life Sciences, PRIA delivers unparalleled expertise to navigate complex reimbursement landscapes.
Our experts in reimbursement strategy and healthcare economics outcomes research provide guidance to medical device companies by navigating challenging and uncertain reimbursement pathways, determining the coding, coverage, and payment for market access and adoption of new technologies. Our strategic approach accelerates the adoption of healthcare innovation, facilitating market access and appropriate reimbursement, today and into the future.
PRIA is specialty-agnostic, supporting the entire product journey from concept development to successful commercialization. For additional information please visit our website at www.PRIAHealthcare.com
RegenLab USA
Website: https://www.regenlabusa.com/
RegenLab USA LLC is a leading manufacturer specializing in advanced technologies for regenerative medicine, with a core focus on autologous platelet-rich plasma (PRP) therapies. Our commitment to patient safety, product innovation, and clinical excellence is underscored by our achievement of MDSAP certification, demonstrating adherence to the highest international quality and regulatory standards.
With a fully in-house sterilization process and a new state-of-the-art manufacturing facility in Jersey City, New Jersey, RegenLab ensures precise control over product sterility, consistency, and integrity—delivering manufacturing excellence rare within the industry. Our proprietary PRP technology is backed by extensive intellectual property coverage, supported by over 300 scientific publications and five clinical study books that validate our leadership in regenerative science.
As we continue to expand our reach, we are actively seeking partnership opportunities with healthcare providers, distributors, and research institutions dedicated to advancing the field of regenerative therapies. RegenLab USA LLC remains steadfast in its mission to deliver scientifically grounded solutions that empower medical innovation and improve patient outcomes.
SolasCure
Website: https://www.solascure.com/
SolasCure is developing Aurase Wound Gel (AWG), a novel enzymatic debrider designed to improve debridement and biofilm management in chronic wound care. AWG utilizes tarumase, an enzyme inspired by larval therapy, to offer effective, selective, and continuous debridement while protecting healthy tissue. By consistently clearing wounds of slough and biofilm, AWG fosters an optimal healing environment. Unlike conventional methods, AWG's safety profile supports 'maintenance' debridement to prevent the reoccurrence of slough and infection, making it a strong fit for current wound care protocols. This approach aims for faster healing, better patient outcomes, and potential cost savings for healthcare systems.
Transdiagen
Website: https://www.transdiagen.com/
Transdiagen (TDG) is a precision medicine company developing diagnostics and drugs for chronic wound healing and tissue regeneration. TDG’s Drug-Target Interaction (DTI) prediction network utilises patented gene signature biomarkers to power their drug discovery platform.
TDG have developed a range of PCR based, gene expression diagnostics. Our most advanced diagnostic “WD14” stratifies venous leg ulcer patients into those that will heal under standard of care from those that will not. TDG also have a range of drug development programs generated by our DTI prediction network, with patents granted for our lead drug candidate.
TDG has now launched a service whereby data generated from our proprietary models, (molecular mechanisms of disease understanding) for drug and device development can be accessed across a range of indications and interventions from discovery through to post-market analysis. Partnering with TDG and accessing data from our In Vivo and Ex Vivo models provide:
- Cell function mechanisms of action for chronic wounds,
- Functional insights that support product development and performance improvements, &
- Route to incremental IP and additional product lines.
Tiger Wound Care
Website: https://tigerbiosciences.com/
Zero Gravity Skin
Website: https://www.zerogravityskin.com/
ZERO GRAVITY SKIN was founded with one goal in mind; to develop and deliver the safest and most effective pain management and anti-aging Medical devices to consumers across the globe.
Zero Gravity is committed to produce the most effective LED (Light Emitting Diodes) light therapy for chronic pain and facial skin rejuvenation in the industry.
The sophisticated technology behind InfraRed Light Therapy is supported by many leading board
certified Dermatologists and Plastic Surgeons across the globe.
Zero Gravity devices are FDA-Cleared Class 11 medical devices.
Coffee Partner
Vaporox
Website: https://vaporox.com/
Having received FDA 510(k) clearance for its patented VHT-200 wound healing medical device on March 23. 2023, Vaporox is marketing its Vaporous Hyperoxia Therapy (VHTÔ), a breakthrough technology for healing diabetic foot ulcers (DFUs) to medical doctors and podiatrist in private practice.
Both clinical studies and commercial results show that Vaporox’s VHT-200 heals 85% of the DFUs that resist “the standard of care,” making it by far the best DFU treatment available. VHT gets comparable results in real world use as well.
The VHT-200 brings advanced wound care to private providers’ offices. It also greatly improves practice economics. With VHT treatments reimbursed by a Category 1 CPT code, adoption of VHT will typically improve a provider’s DFU healing efficacy by 2x to 3x while increasing their per-patient revenues by 5x to 6x, while allowing them to provide Advanced Wound Care, in their practice.
Delivering a VHT treatment requires only about 10 minutes of a med tech’s time. The device is nearly maintenance free, and the continuously reports its status via IoT, allowing proactive field support.
Vaporox’s “pay-per-treatment” sales model enables provider adoption with no up-front cost or risk. This produces recurring revenue for the company while shortening sales cycles and minimizing sales and marketing costs.
VHT treatment of all newly-occurring U.S. DFUs would require about 22,000 VHT-200s and yield Vaporox revenues of about $1.6 billion/year, with very high margins.
Media Partner
SmartTRAK
Website: https://www.smarttrak.com/
SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s propriety methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services.
